Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Kessler, SM; Leber, B; Hoppstädter, J; Golob-Schwarzl, N; Hofer, EM; Schultheiss, CS; Mischinger, HJ; Liegl-Atzwanger, B; Lackner, C; Stiegler, P; Haybaeck, J.
Diethylnitrosamine (DENA) recapitulates formation of hepatic angiosarcoma in pigs.
PLoS One. 2019; 14(5):e0214756-e0214756 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Authors Med Uni Graz:
Golob-Schwarzl Nicole
Haybäck Johannes
Kessler Sonja
Lackner Karoline
Leber Bettina
Liegl-Atzwanger Bernadette
Mischinger Hans-Joerg
Stiegler Philipp
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
Abstract:
Primary hepatic angiosarcoma is a rare tumor with poor prognosis. The aim of this study was to generate a new angiosarcoma model to improve research on hepatic angiosarcoma. Pigs sus scrofa were treated with different regimens of diethylnitrosamine (DENA). Tissues were analyzed by histology and immunohistochemistry. Serum parameters were determined. Angiosarcoma tissue was investigated for chromosomal aberrations by aCGH analysis. Animals of almost all different treatment regimens developed a multitude of variable liver lesions. Different tumor types such as granulation tissue type, cellular-like, hyalinization necrosis-like, angiosarcoma-like, dysplastic nodule-like, hepatocellular-like, glandular structure-like, and leiomyoma-like lesions were observed. Weekly treatment with 15 mg/kg for up to 52 weeks or a single shot of 200 mg/kg DENA led to the development of hepatic angiosarcomas. aCGH analysis of angiosarcoma tissue revealed increased alterations in tumors compared to non-tumorous tissue. Most of the chromosomal alterations were found on chromosomes 6, 7, 12, and 14. In this preliminary study treatment of sus scrofa with weekly injections of 15 mg/kg DENA results in a new model for primary hepatic angiosarcoma. This model may help to shed light on the pathomechanisms of primary hepatic angiosarcoma and might therefore open new treatment options.

© Meduni GrazImprint